Formulary Decisions

Search for the outcome of decisions made by the Formulary Committee

Filter
Select filter(s)
Certolizumab pegol
Cimzia
Routinely available
SMC (SMC2132)
29/03/2023

Indication

Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy

Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy

Therapeutic Area

Skin

Status Description

Routinely available in line with national guidance

Formulation

200mg solution for injection in pre-filled syringe and pen

Comments

-

Link to Advice

SMC2132

Advice Published

08/04/2019

SMC Submission Type

Full

SMC Status

Restricted